Ellen Strahlman Purchases 19,702 Shares of Hyperion DeFi (NASDAQ:HYPD) Stock

Hyperion DeFi, Inc. (NASDAQ:HYPD) Director Ellen Strahlman acquired 19,702 shares of Hyperion DeFi stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average cost of $3.14 per share, for a total transaction of $61,864.28. Following the purchase, the director owned 95,150 shares of the company’s stock, valued at $298,771. The trade was a 26.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Hyperion DeFi Price Performance

Shares of NASDAQ HYPD opened at $3.67 on Monday. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $29.99 million, a PE ratio of -0.91 and a beta of 2.80. The firm has a fifty day simple moving average of $5.31 and a 200 day simple moving average of $7.59. Hyperion DeFi, Inc. has a twelve month low of $0.85 and a twelve month high of $17.99.

Hyperion DeFi (NASDAQ:HYPD) last posted its quarterly earnings data on Friday, November 14th. The company reported $0.05 earnings per share for the quarter. The firm had revenue of $0.36 million during the quarter. Hyperion DeFi had a negative return on equity of 119.59% and a negative net margin of 62,238.41%. On average, sell-side analysts forecast that Hyperion DeFi, Inc. will post -41.6 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on HYPD. Weiss Ratings restated a “sell (d-)” rating on shares of Hyperion DeFi in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Finally, Cantor Fitzgerald assumed coverage on shares of Hyperion DeFi in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 price target for the company. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Hyperion DeFi currently has an average rating of “Hold” and a consensus price target of $3.00.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.